Cadila Healthcare, a Rs 2850 crore Ahmedabad based pharma major, has posted satisfactory performance during the first quarter ended June 2009 on account of robust performance in the US. The company's consolidated net profit went up by 39.1 per cent to Rs 124.79 crore from Rs 90 crore in the corresponding period of last year. Its consolidated net sales also increased by 28.4 per cent to Rs 880.31 crore from Rs 685.71 crore.

An overall 66 per cent growth in formulation exports was driven by growth in US Europe and the emerging markets. Its sales in US moved up 81 per cent to Rs 147.90 crore. The group launched mycophenolate mofetil tablets and capsules in May 2009. In Europe, the group registered growth of 39 per cent and posted sales of Rs 63.80 crore. Four new products were launched in the French generics market during the quarter. Exports to emerging markets grew by 86 per cent with sales of Rs 52.60 crore.

Its domestic formulations business registered a growth of 13 per cent. It launched 17 new products, including line extensions, and two of these - Trozyd in the urology segment and Fluticone FT in the respiratory segment - were launched for the first time in India. The group's consumer business, now spearheaded by Zydus Wellness, grew by a whopping 28 per cent. The quarter also witnessed the launch of an exclusive skincare range for men under the Everyuth banner.

Zydus Hospira, the group's 50:50 joint venture with Hospira to manufacture oncology injectibles commenced commercial operations in May 2009 and has posted sales of Rs 46.80 crore.

Augmenting its research pipeline, the group filed its 7th IND - ZYD1, a novel GLP-1 agonist molecule with the DCGI. ZYD1 is a novel candidate in the class of anti-diabetic agents known as incretin mimetics and has displayed a better efficacy and safety profile.

Further strengthening its regulatory pipeline, the group filed 3 DMFs with US FDA, taking cumulative filings to 79 DMFs. During the quarter, the group received approvals for 6 ANDAs, taking the cumulative number of US ANDA approvals to 48. The group also received 3 new product approvals for the French market, taking the cumulative approvals to 31 approvals.